Skip to main content
Premium Trial:

Request an Annual Quote

CellMax Life Receives NT$23M Grant From Taiwan Government for Cancer Early Detection Test

NEW YORK (GenomeWeb) – Liquid biopsy firm CellMax Life said today that it has received an NT$23 million ($760,846) grant from the Taiwan Government Industrial Development Bureau Ministry of Economic Affairs. 

The company plans to use the funding to accelerate its efforts to automate its circulating tumor cell-based technology, and to advance plans for world-wide commercialization of its early cancer detection platform CMxTM.

CellMax Life President and CEO Atul Sharan said in a statement that the grant will allow the company to more rapidly expand the availability of the CMxTM platform and the blood-based screening test the company has developed for colorectal cancer, which it launched in Taiwan last year.